Cardiogenic shock primary prevention
|
Cardiogenic Shock Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cardiogenic shock primary prevention On the Web |
|
American Roentgen Ray Society Images of Cardiogenic shock primary prevention |
|
Risk calculators and risk factors for Cardiogenic shock primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2] Syed Musadiq Ali M.B.B.S.[3] James Nasr[4]
Cardiogenic shock primary prevention
Overview
Primary prevention of cardiogenic shock has two complementary goals: prevention of the cardiovascular diseases that most commonly lead to shock, especially acute myocardial infarction and heart failure, and prevention of progression from acute cardiac disease to established shock through early recognition of at-risk or preshock states. Because acute myocardial infarction remains the most common cause of cardiogenic shock, prevention of atherosclerotic cardiovascular disease and timely treatment of acute coronary syndromes are central preventive strategies.[1][2]
This microchapter focuses on preventing incident cardiogenic shock and preventing progression to shock in high-risk acute cardiac presentations. Long-term management after cardiogenic shock is addressed in the secondary prevention microchapter.
Prevention of underlying cardiovascular disease
Risk assessment
Primary prevention begins with structured assessment of atherosclerotic cardiovascular disease risk. The 2026 ACC/AHA dyslipidemia guideline and the 2025 AHA/ACC blood pressure guideline use the AHA PREVENT equations for quantitative cardiovascular risk estimation in contemporary adults.[3][4]
Risk assessment should identify both short-term and lifetime risk contributors, including age, blood pressure, lipids, diabetes, kidney disease, tobacco exposure, obesity, family history, prior pregnancy-related risk factors when relevant, social determinants of health, and established subclinical or clinical cardiovascular disease.[5][6]
Dyslipidemia prevention
The 2026 ACC/AHA dyslipidemia guideline defines PREVENT-ASCVD 10-year risk categories as low risk (<5%), borderline risk (5% to <7.5%), intermediate risk (7.5% to <20%), and high risk (≥20%). For primary prevention, the guideline recommends statin therapy for adults with high risk (class 1, level A), statin therapy for adults with intermediate risk (class 1, level A), and statin therapy after clinician-patient risk discussion for adults with borderline risk when risk-enhancing factors are present (class 2a, level A).[3]
Blood pressure prevention
The 2025 AHA/ACC blood pressure guideline recommends antihypertensive drug therapy for all adults with confirmed average blood pressure ≥140/90 mm Hg regardless of calculated risk. The guideline also recommends antihypertensive drug therapy at a threshold of ≥130/80 mm Hg for adults with clinical cardiovascular disease, diabetes, chronic kidney disease, or PREVENT 10-year cardiovascular disease risk ≥7.5%. For adults with stage 1 hypertension at low cardiovascular disease risk, lifestyle modification should be attempted first, with drug therapy initiated if blood pressure is not at goal in 3 to 6 months. The recommended office blood pressure goal is <130/80 mm Hg for adults treated with antihypertensive medication.[4][7]
Risk-factor modification
| Prevention domain | Preventive intervention | Clinical relevance to cardiogenic shock prevention |
|---|---|---|
| Dyslipidemia | Use PREVENT-ASCVD risk estimation, clinician-patient risk discussion, statin therapy when indicated, and additional lipid-lowering therapy for selected high-risk patients. | Reduces incident myocardial infarction, thereby reducing the most common pathway to cardiogenic shock.[3] |
| Hypertension | Confirm elevated blood pressure with proper measurement; treat according to 2025 AHA/ACC blood pressure thresholds, risk category, and target blood pressure. | Reduces coronary disease, heart failure, stroke, chronic kidney disease, and hypertensive cardiac remodeling.[4] |
| Diabetes mellitus | Prevent and treat diabetes using lifestyle, weight management, cardioprotective glucose-lowering therapy when indicated, and aggressive risk-factor control. | Diabetes increases risk of myocardial infarction, multivessel coronary disease, heart failure, and adverse outcomes after acute coronary syndrome.[5] |
| Tobacco exposure | Provide behavioral counseling and pharmacotherapy for smoking cessation when appropriate. | Smoking cessation reduces acute coronary syndrome risk and recurrent ischemic events.[5] |
| Diet | Encourage a heart-healthy dietary pattern rich in vegetables, fruits, legumes, nuts, whole grains, and fish, with reduced intake of trans fat, processed meats, refined carbohydrates, and sugar-sweetened beverages. | Improves cardiovascular risk factors and lowers ASCVD risk.[5] |
| Physical activity | Encourage regular aerobic and resistance activity adapted to age, comorbidity, and functional status. | Improves blood pressure, insulin sensitivity, weight, cardiorespiratory fitness, and cardiovascular risk.[5] |
| Obesity | Treat overweight and obesity with lifestyle intervention and evidence-based weight management strategies. | Reduces cardiometabolic risk and may reduce progression to heart failure. |
| Aspirin | Low-dose aspirin may be considered only for select adults aged 40 to 70 years at higher ASCVD risk without increased bleeding risk; routine aspirin use for primary prevention is harmful in adults older than 70 years. | Aspirin has a limited primary prevention role because bleeding risk often offsets ischemic benefit.[5] |
| Sleep and global cardiovascular health | Assess sleep, physical activity, tobacco exposure, weight, blood pressure, glucose, and lipids as part of comprehensive cardiovascular prevention. | Global cardiovascular health optimization reduces upstream risk of myocardial infarction and heart failure. |
Heart failure prevention
Heart failure prevention is also relevant because heart failure-related cardiogenic shock is a major non-AMI shock phenotype. The PREVENT equations include heart failure endpoints, and modern cardiovascular prevention should address hypertension, diabetes, obesity, kidney disease, coronary disease, and cardiometabolic risk to reduce incident heart failure.[4][3]
Prevention of progression from acute cardiac disease to shock
At-risk and preshock states
The SCAI shock classification defines stage A as patients at risk for cardiogenic shock without current signs or symptoms of shock, and stage B as beginning shock with hemodynamic instability but without hypoperfusion. These stages identify patients in whom prevention of progression is a major goal.[8][9]
Patients at increased risk for developing cardiogenic shock after acute myocardial infarction include those with older age, prior myocardial infarction, diabetes mellitus, reduced left ventricular ejection fraction, large infarct size, anterior infarction, multivessel coronary artery disease, delayed presentation, female sex, and peripheral or cerebrovascular disease.[10][11]
Acute myocardial infarction prevention strategy
Early recognition and treatment of acute myocardial infarction are essential to prevent progression to cardiogenic shock. In the SHOCK trial registry, the median time from symptom onset to cardiogenic shock onset was approximately 5.5 hours, and 25.9% of patients developed shock 24 hours or more after symptom onset, creating a time window for early recognition and intervention.[1]
The 2025 ACC/AHA/ACEP/NAEMSP/SCAI acute coronary syndromes guideline gives emergency culprit-vessel revascularization by PCI or CABG a class 1, level B-R recommendation in patients with ACS and cardiogenic shock or hemodynamic instability, irrespective of time from symptom onset.[12] In an observational analysis cited in contemporary guidance, each 10-minute delay in primary PCI after 60 minutes from first medical contact was associated with an additional 3 to 4 deaths per 100 treated patients.[12]
Avoiding precipitating medications in acute MI
Early beta-blocker therapy after acute myocardial infarction requires careful patient selection. In the COMMIT trial, early high-dose intravenous then oral metoprolol reduced reinfarction and ventricular fibrillation but increased cardiogenic shock risk, mainly during the first 24 hours.[13] The 2025 acute coronary syndromes guideline recommends early low-dose oral beta-blocker therapy only in patients without contraindications and discontinuation if new or worsening heart failure or cardiogenic shock develops.[12]
Beta-blockers should be avoided or delayed in acute heart failure, Killip class II-IV, evidence of low cardiac output, risk for cardiogenic shock, significant bradycardia, or high-grade atrioventricular block.[12]
The EARLY-BAMI trial randomized 683 patients with ST-segment elevation myocardial infarction undergoing primary PCI and found no significant reduction in infarct size with early intravenous metoprolol, but also did not show an increase in cardiogenic shock, suggesting that beta-blocker risk may be dose- and population-dependent.[14]
The REDUCE-AMI trial found no benefit of long-term beta-blocker therapy after myocardial infarction with preserved left ventricular ejection fraction, raising questions about beta-blocker duration after revascularized myocardial infarction without heart failure.[15]
Serial reassessment and early shock recognition
Cardiogenic shock is dynamic. Patients can progress from at-risk or preshock states to classic shock over hours. The Critical Care Cardiology Trials Network reported a stepwise mortality gradient across the preshock-to-shock continuum, with mortality rising from approximately 4% in isolated low cardiac output to 24% in SCAI stage C cardiogenic shock.[16]
Patients at risk for cardiogenic shock should undergo serial reassessment rather than one-time triage. The 2025 ACC Expert Consensus Statement emphasizes early bedside recognition using symptoms, blood pressure assessment, shock risk identification, perfusion markers, ECG, cardiac imaging, and team-based reassessment.[17]
Serial reassessment should include:
- Blood pressure and pulse pressure
- Heart rate and rhythm
- Mental status
- Peripheral perfusion and skin temperature
- Urine output
- Serial lactate
- ECG reassessment when ischemia or arrhythmia is suspected
- Bedside echocardiography when ventricular function, mechanical complications, or volume status are uncertain
- Reassignment of SCAI shock stage when clinical status changes
Areas of uncertainty
- The optimal use and duration of beta-blocker therapy after myocardial infarction depends on left ventricular function, infarct type, arrhythmia risk, revascularization status, and hemodynamic stability. COMMIT supports caution with early high-dose intravenous therapy, EARLY-BAMI suggests selected early intravenous use may be safer than older high-dose regimens, and REDUCE-AMI questions long-term benefit after myocardial infarction with preserved ejection fraction.[13][14][15]
- Primary prevention strategies reduce upstream risk of myocardial infarction and heart failure, but no randomized trial tests a primary-prevention strategy with incident cardiogenic shock as the primary endpoint.
- PREVENT-based risk estimation may change medication eligibility compared with older pooled cohort equation-based approaches; clinician-patient risk discussion remains important.[18]
Multidisciplinary shock team activation
The 2022 AHA/ACC/HFSA heart failure guideline gives management by a multidisciplinary team experienced in shock a class 2a, level B-NR recommendation.[19] Early shock team activation may help prevent progression by accelerating diagnosis, risk stratification, reperfusion, hemodynamic assessment, mechanical circulatory support decisions, and transfer to advanced shock centers when needed.[17]
Practical primary prevention approach
- Prevent upstream cardiovascular disease with guideline-directed ASCVD risk assessment, lipid management, blood pressure control, diabetes prevention and treatment, smoking cessation, healthy diet, physical activity, and weight management.
- Use PREVENT-ASCVD and PREVENT-CVD risk estimation when applying contemporary dyslipidemia and blood pressure prevention guidelines.
- Identify patients at risk for cardiogenic shock during acute myocardial infarction, acute decompensated heart failure, myocarditis, severe valvular disease, arrhythmia, or other acute cardiac illness.
- Use SCAI stage A and B to recognize at-risk and beginning-shock states before overt hypoperfusion develops.
- Treat acute myocardial infarction rapidly, with urgent reperfusion when indicated.
- Avoid early high-dose intravenous beta-blockers and other negative inotropic drugs in patients with heart failure, low-output physiology, bradyarrhythmia, or risk for cardiogenic shock.
- Monitor high-risk hospitalized patients with serial vital signs, perfusion assessment, urine output, lactate, ECG, and echocardiography when indicated.
- Activate a multidisciplinary shock team early when shock is suspected, evolving, or likely to require invasive hemodynamic assessment, revascularization, or mechanical circulatory support.
Common pitfalls
- Treating primary prevention of cardiogenic shock as separate from prevention of myocardial infarction and heart failure
- Using outdated risk tools without contemporary ASCVD and blood pressure guideline context
- Omitting guideline class and level of evidence when applying lipid-lowering or blood pressure prevention recommendations
- Failing to recognize SCAI stage A or B patients as candidates for intensified monitoring
- Assuming absence of hypotension excludes evolving cardiogenic shock
- Delaying reperfusion in acute myocardial infarction while shock physiology is evolving
- Giving early high-dose intravenous beta-blockers to patients with low-output physiology, heart failure, bradycardia, or shock risk
- Using aspirin routinely for primary prevention in older adults or patients with increased bleeding risk
- Performing only one-time assessment rather than serial reassessment in high-risk acute cardiac illness
- Waiting for established multiorgan hypoperfusion before activating a shock team
References
- ↑ 1.0 1.1 Samsky MD, Morrow DA, Proudfoot AG; et al. (2021). "Cardiogenic Shock After Acute Myocardial Infarction". JAMA. 326 (18): 1840–1850. doi:10.1001/jama.2021.18323.
- ↑ Lüsebrink E, Binzenhöfer L, Adamo M; et al. (2024). "Cardiogenic Shock". Lancet. 404 (10466): 2006–2020. doi:10.1016/S0140-6736(24)01818-X.
- ↑ 3.0 3.1 3.2 3.3 Blumenthal RS, Morris PB, Gaudino M; et al. (2026). "2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia". Journal of the American College of Cardiology. doi:10.1016/j.jacc.2025.11.016.
- ↑ 4.0 4.1 4.2 4.3 Jones DW, Ferdinand KC, Taler SJ; et al. (2025). "2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults". Journal of the American College of Cardiology. 86 (18): 1567–1678. doi:10.1016/j.jacc.2025.05.007.
- ↑ 5.0 5.1 5.2 5.3 5.4 5.5 Arnett DK, Blumenthal RS, Albert MA; et al. (2019). "2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease". Journal of the American College of Cardiology. 74 (10): e177–e232. doi:10.1016/j.jacc.2019.03.010.
- ↑ Lloyd-Jones DM, Braun LT, Ndumele CE; et al. (2019). "Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease". Journal of the American College of Cardiology. 73 (24): 3153–3167. doi:10.1016/j.jacc.2018.11.005.
- ↑ Abbasi J (2025). "What to Know About the New Blood Pressure Guidelines". JAMA. doi:10.1001/jama.2025.17664.
- ↑ Baran DA, Grines CL, Bailey S; et al. (2019). "SCAI Clinical Expert Consensus Statement on the Classification of Cardiogenic Shock". Catheterization and Cardiovascular Interventions. 94 (1): 29–37. doi:10.1002/ccd.28329.
- ↑ Naidu SS, Baran DA, Jentzer JC; et al. (2022). "SCAI SHOCK Stage Classification Expert Consensus Update". Journal of the American College of Cardiology. 79 (9): 933–946. doi:10.1016/j.jacc.2022.01.018.
- ↑ Hands ME, Rutherford JD, Muller JE; et al. (1989). "The In-Hospital Development of Cardiogenic Shock After Myocardial Infarction: Incidence, Predictors of Occurrence, Outcome and Prognostic Factors". Journal of the American College of Cardiology. 14 (1): 40–46. doi:10.1016/0735-1097(89)90051-X.
- ↑ Pöss J, Köster J, Fuernau G; et al. (2017). "Risk Stratification for Patients in Cardiogenic Shock After Acute Myocardial Infarction". Journal of the American College of Cardiology. 69 (15): 1913–1920. doi:10.1016/j.jacc.2017.02.027.
- ↑ 12.0 12.1 12.2 12.3 Rao SV, O'Donoghue ML, Ruel M; et al. (2025). "2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes". Journal of the American College of Cardiology. doi:10.1016/j.jacc.2024.11.009.
- ↑ 13.0 13.1 Chen ZM, Pan HC, Chen YP; et al. (2005). "Early Intravenous then Oral Metoprolol in 45,852 Patients With Acute Myocardial Infarction: Randomised Placebo-Controlled Trial". Lancet. 366 (9497): 1622–1632. doi:10.1016/S0140-6736(05)67661-1.
- ↑ 14.0 14.1 Roolvink V, Ibáñez B, Ottervanger JP; et al. (2016). "Early Intravenous Beta-Blockers in Patients With ST-Segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention". Journal of the American College of Cardiology. 67 (23): 2705–2715. doi:10.1016/j.jacc.2016.03.522.
- ↑ 15.0 15.1 Yndigegn T, Lindahl B, Mars K; et al. (2024). "Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction". The New England Journal of Medicine. 390 (15): 1372–1381. doi:10.1056/NEJMoa2401479.
- ↑ Patel SM, Berg DD, Bohula EA; et al. (2024). "Continuum of Preshock to Classic Cardiogenic Shock in the Critical Care Cardiology Trials Network Registry". JACC: Heart Failure. 12 (9): 1625–1635. doi:10.1016/j.jchf.2024.06.009.
- ↑ 17.0 17.1 Sinha SS, Morrow DA, Kapur NK, Kataria R, Roswell RO (2025). "2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Evaluation and Management of Cardiogenic Shock". Journal of the American College of Cardiology. 85 (16): 1618–1641. doi:10.1016/j.jacc.2025.02.018.
- ↑ Diao JA, Shi I, Murthy VL; et al. (2024). "Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk Equations". JAMA. 332 (12): 989–1000. doi:10.1001/jama.2024.12537.
- ↑ Heidenreich PA, Bozkurt B, Aguilar D; et al. (2022). "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure". Journal of the American College of Cardiology. 79 (17): e263–e421. doi:10.1016/j.jacc.2021.12.012.